Stents Clinical Trial
Official title:
A Study of Platelet Function Test in the Application of Prevention of Ischemic Events After Stent Placement in Intracranial Aneurysms
This study was designed to identify high platelet reactivity (HPR) who might have in-stent thrombosis in unruptured aneurysm with intracranial stent placement with light transmittance platelet aggregometry (LTA). For HPR patients, higher ischemic stroke rate maybe occurred, and we hypothesis that dose adjustment of aspirin and clopidogrel based on LTA monitoring maybe reduces the rate of ischemic stroke compared to a standard strategy after intracranial stent implantation at early periprocedural period and 1 month follow-up period.
For the patients of unruptured intracranial aneurysms with stent placement, standard
antiplatelet therapy (100mg aspirin + 75mg clopidogrel) is considered to be the most
effective antiplatelet regimen in reducing ischemic complications. However, despite the use
of standard antiplatelet therapy, a number of patients continue to have ischemic events. A
hypothesis is that high platelet reactivity (HPR) patients identified by platelet function
test have higher ratio of the ischemic events, and dose adjustment of HPR patients reduces
the rate of the ischemic complications at early periprocedural period and follow-up period.
Objectives: The study aim to evaluated the superiority of the strategy of platelet function
test(Monitoring Arm) with the modified strategy in HPR patients compared to the standard
strategy (Conventional Arm) whether reduce the primary endpoint after intracranial stent
implantation at early periprocedural period (7 days) and 1 months follow-up period.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01900691 -
Removal of the Evolution® Esophageal Stent - Fully Covered
|
N/A | |
Recruiting |
NCT05872074 -
Immediate and Short Term Outcomes for Using Drug Coated Balloons in Treating Coronary Bifurcation Lesions
|
N/A | |
Enrolling by invitation |
NCT01172158 -
SMS Reminder for Forgotten Ureteral Stents
|
N/A | |
Completed |
NCT04115696 -
Biodegradable Stent Implantation in Biliary Benign Strictures.
|
||
Completed |
NCT01124942 -
MGuard Stent in ST-elevation Myocardial Infarction
|
N/A | |
Completed |
NCT02811796 -
Angio-based Fractional Flow Reserve to Predict Adverse Events After Stent Implantation
|
||
Recruiting |
NCT01997242 -
The Surgery After Stenting (SAS) Registry
|
N/A | |
Completed |
NCT01056744 -
Optical Coherence Tomography to Evaluate Paclitaxel-Eluting Balloons and Everolimus-Eluting Coronary Stents
|
Phase 4 | |
Completed |
NCT00691314 -
Efficacy and Safety of Stent Implantation in Symptomatic Extra- and Intracranial Artery Stenosis
|
N/A | |
Completed |
NCT00180479 -
SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
|
Phase 3 | |
Completed |
NCT03521700 -
Compare Effects of Intensive Versus Conventional Lipid-lowering Therapy in Patients With Severe Atherosclerotic Renal Artery Stenosis Undergoing Stent Placement
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT01160900 -
FIT (Fast Infarction Treatment): Complete Revascularization During Primary Percutaneous Coronary Intervention (PCI) Can be Achieved Safely With an Improved Clinical Outcome During the Indexed Hospitalization.
|
Phase 3 | |
Completed |
NCT00937573 -
Xience V at Wake Forest University Baptist Medical Center (WFUBMC)
|
N/A | |
Recruiting |
NCT00637104 -
European Multicenter, Randomized, Comparative Efficacy/Safety Study of the Mar-Tyn TiN-Coated Stent
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03375411 -
First-in-Man Study: Safety and Efficacy of INC-1 Bare Metal Stent in the Novo Coronary Lesions.
|
N/A | |
Completed |
NCT01962168 -
Evolution® Biliary Stent System Clinical Study
|
N/A | |
Completed |
NCT00769938 -
WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)
|
Phase 4 | |
Completed |
NCT05556668 -
Percutaneous Biodegradable Biliary Stents for the Treatment of Benign Biliary Strictures.
|
||
Terminated |
NCT03119012 -
P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold
|
Phase 4 |